Paracetamol for Cancer Pain

• Status: Unknown status
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Randomised, double-blind placebo controlled cross-over trial

Main goal:

Optimize the medical pain treatment for patients with advanced cancer disease

Study goal:

Measure paracetamol's additional analgesic effect in a situation where the patient is concomitantly treated with oral opioids eqv. morphine > 100 mg/d.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Haraldsplass Deaconess Hospital
• Treatments: Acetaminophen

Criteria

Inclusion Criteria:

• Adults (> 18 years) of both sexes

• Diagnosed with advanced cancer disease

• Ongoing medicinal pain relief treatment in stable dosing with oral opiates equivalent to > 100 mg oral morphine daily

• NRS median pain score last 24 hrs > 4

• Able to take tablets (paracetamol) orally

Exclusion Criteria:

• Mental or physical deficiency precluding data collection.

• Reduced liver function judged with bilirubin, INR and transaminases

• Anticoagulation with warfarin

• Ongoing use of NSAIDs or 5-HT3 antagonists, or use of such drugs last week

• Ongoing palliative radiation treatment or radiation treatment during the last 4 weeks.